Hospital and Laboratory

Antimicrobial Resistance is undermining modern medicine and putting patients at risk of premature death. bioMérieux is committed to preserving antibiotic efficacy with the right diagnostic tests that guide appropriate and responsible use of antibiotics to ensure they remain lifesaving for posterity.

When time is critical, you need accurate information, and you need it fast. bioMérieux is your partner along the sepsis management pathway, offering the most comprehensive solution for sepsis diagnostics to optimize antibiotic therapy for better patient care.

When a patient is suffering from respiratory symptoms, it’s challenging to know what’s causing the illness without diagnostic results. Our respiratory solutions provide fast, comprehensive, and accurate answers for optimized patient care and to fight AMR.

From our most advanced syndromic approach to our traditional methods, bioMérieux has comprehensive diagnostic solutions to help clinicians identify GI pathogens causing gastroenteritis, making it easier to treat patients and improve outcomes.

Because every COVID-19 patient comes with a unique profile and experiences the disease differently, patient management means asking the right questions, finding the right answers and providing appropriate care the entire length of the patient pathway.

When coupled with a clinical pretest probability assessment model, VIDAS® D-Dimer Exclusion™ II aids clinicians in safely ruling out deep vein thrombosis (DVT) and pulmonary embolism (PE) in outpatient cases involving suspected DVT or PE.

Acute kidney injury (AKI) is a syndrome that consists of an abrupt loss of kidney function. It affects more than 70% of intensive care units (ICU) patients^1,2. In critical care settings, current diagnosis tools are lagging, so prevention is key. An early implementation of nephroprotective measures can indeed reduce the incidence of both moderate and severe stages of AKI.

bioMérieux offers solutions for diagnosing both active and latent tuberculosis to prevent the development of active tuberculosis and stop the spread of tuberculosis. 

Early and accurate diagnosis of cancer substantially increases the chances of successful treatment. bioMérieux is committed to developing diagnostic tools that improve early detection of cancer, as well as monitor the efficacy of treatment to help clinicians make relevant clinical decisions in their daily practice.

Robust immunoassay testing with fertility, adrenocortical, and thyroid hormone assays greatly contribute to the accuracy and reliability of results used to diagnose, treat, and monitor patients rapidly and safely.